Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Queen Mary University of London, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Université Paris-Saclay, Institut Gustave Roussy, Marqués de Valdecilla University Hospital, Asan Medical Center, University of Ulsan, National Cancer Center Hospital East, University of Antwerp, Astellas Pharma (United States), Seagen (United States), Yale University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3133744109